By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Find the epitope specificity of your T-cell receptors with
machine learning

Find and track the T cells that matter

Accelerate the development of your therapeutics and diagnostics by truly understanding T-cell responses. ImmuneWatch’s machine learning platform can annotate the epitope specificity of T-cell receptor (TCR) sequences, turning TCR repertoires into clinically actionable data.

How our technology works

TCR sequencing offers you an unprecedented deep insight in the composition of the T-cell receptor repertoire of a patient and its dynamics in response to a T-cell therapeutic or vaccine.

TCR sequencing can be performed on PBMCs, stimulated cells or tissue samples. ImmuneWatch’s technology is compatible with single cell or -bulk sequencing approaches.

A bottle-neck in the analysis of TCR repertoires is the annotation of the epitope-specificity of TCRs. Based on > 7 years of research, ImmuneWatch has developed explainable machine learning algorithms (IMW-DETECT) that can link TCRs to their cognate epitope sequences. Find your therapy-, vaccine- or pathogen-specific TCRs in less than 2 minutes.

ImmuneWatch is dedicated to offer a complete solution, from sequencing to immunoinformatics analysis. As experts in immunology and bioinformatics ImmuneWatch is able to provide a complete immunoinformatic pipeline from FASTQ to interactive reports.

Predict what parts of a pathogen will be most effective in a vaccine. ImmuneWatch’s unique algorithms provide not only insights in epitope presentation, but also into the prevalence of T cells that can potentially bind the peptide-MHC complexes (patent pending).

"Together with ImmuneWatch we were able to assess vaccine-induced T-cell signatures in our unique longitudinal sample collection of cancer patients. Based on antibody titers, it has previously been shown that cancer patients induce a weaker response towards COVID19 vaccines. T-cell immunity in this context is far less characterized and understood. Thanks to the ImmuneWatch DETECT platform we were able to take a deep dive into the SARS-CoV-2-specific T-cell response of our cancer patient cohort. "

Prof. Dr. Eva Lion & Prof. Dr. Timon Vandamme
University of Antwerp - University Hospital Antwerp

Find the epitope-specificity of your TCRs today